Nektar Therapeutics

Research Nektar Therapeutics (NKTR) on Bullrun: market cap USD 1.33B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNKTR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.33B
• Financial periodFY2025
• RevenueUSD 55.23M
• Revenue growth-43.9%
• Net income-USD 164.00M
• Free cash flow-USD 208.68M
• Gross margin100.0%

Valuation Snapshot

latest market cap is USD 1.33B.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases;

Frequently asked questions

What is Nektar Therapeutics's market cap?

Nektar Therapeutics's market capitalization is USD 1.33B.

What does Nektar Therapeutics do?

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.